Source 1primary paper2025MED
Toolkit/AKAV Gc epitope-presenting HBcAg chimeric virus-like particle
AKAV Gc epitope-presenting HBcAg chimeric virus-like particle
Also known as: chimeric virus-like particle, epitope-presenting VLP, VLP
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We produced and verified a novel virus-like particle (VLP) by incorporating the neutralizing epitope 1134SVQSFDGKL1142 into a recombinant hepatitis B virus core antigen (HBcAg) scaffold.
Usefulness & Problems
Why this is useful
This chimeric VLP displays a highly conserved neutralizing peptide from the AKAV Gc protein on an HBcAg scaffold. In the study it functioned both as an immunogen and as a coating antigen for indirect ELISA.; epitope-based AKAV vaccine candidate design; coating antigen for indirect ELISA-based AKAV serodetection
Source:
This chimeric VLP displays a highly conserved neutralizing peptide from the AKAV Gc protein on an HBcAg scaffold. In the study it functioned both as an immunogen and as a coating antigen for indirect ELISA.
Source:
epitope-based AKAV vaccine candidate design
Source:
coating antigen for indirect ELISA-based AKAV serodetection
Problem solved
It addresses the lack of explored epitope-based AKAV vaccine designs by packaging a conserved neutralizing epitope into a VLP format. It also provides a defined antigen source for serological detection.; presents a highly conserved AKAV neutralizing epitope on a VLP scaffold; provides a diagnostic antigen for indirect ELISA detection of AKAV antibodies
Source:
It addresses the lack of explored epitope-based AKAV vaccine designs by packaging a conserved neutralizing epitope into a VLP format. It also provides a defined antigen source for serological detection.
Source:
presents a highly conserved AKAV neutralizing epitope on a VLP scaffold
Source:
provides a diagnostic antigen for indirect ELISA detection of AKAV antibodies
Problem links
presents a highly conserved AKAV neutralizing epitope on a VLP scaffold
LiteratureIt addresses the lack of explored epitope-based AKAV vaccine designs by packaging a conserved neutralizing epitope into a VLP format. It also provides a defined antigen source for serological detection.
Source:
It addresses the lack of explored epitope-based AKAV vaccine designs by packaging a conserved neutralizing epitope into a VLP format. It also provides a defined antigen source for serological detection.
provides a diagnostic antigen for indirect ELISA detection of AKAV antibodies
LiteratureIt addresses the lack of explored epitope-based AKAV vaccine designs by packaging a conserved neutralizing epitope into a VLP format. It also provides a defined antigen source for serological detection.
Source:
It addresses the lack of explored epitope-based AKAV vaccine designs by packaging a conserved neutralizing epitope into a VLP format. It also provides a defined antigen source for serological detection.
Published Workflows
Objective: Engineer and verify a chimeric VLP displaying a highly conserved neutralizing AKAV Gc epitope, then evaluate it as both an immunogen and a coating antigen for indirect ELISA detection.
Why it works: The workflow is based on displaying a previously identified highly conserved neutralizing AKAV Gc epitope on an HBcAg VLP scaffold, then testing whether the resulting particle is structurally formed, immunogenic, and usable as an ELISA coating antigen.
presentation of a highly conserved neutralizing AKAV Gc epitope on a VLP scaffoldinduction of antibodies recognizing AKAV Gc and neutralizing AKAVrecombinant VLP engineeringmouse immunizationneutralization assayindirect ELISA
Stages
- 1.Chimeric VLP design and production(library_build)
To generate the engineered VLP that serves as the central immunogen and diagnostic antigen in the study.
Selection: Incorporation of the neutralizing epitope 1134SVQSFDGKL1142 into a recombinant HBcAg scaffold to produce a novel VLP.
- 2.VLP verification(confirmatory_validation)
To confirm that the engineered VLP expressing the AKAV epitope was successfully constructed before biological evaluation.
Selection: Confirmation of successful VLP construction by SDS-PAGE, Western blot, and TEM.
- 3.Mouse immunogenicity evaluation(functional_characterization)
To determine whether the chimeric VLP elicits antibodies against the AKAV Gc antigen.
Selection: Detection of antibody titer targeting the AKAV Gc antigen in sera from VLP-immunized mice.
- 4.In vitro neutralization and replication inhibition testing(secondary_characterization)
To test whether the induced antibodies are functionally antiviral rather than only antigen-binding.
Selection: Neutralizing activity against AKAV and inhibition of viral replication in BHK-21 cells by antisera from VLP-immunized mice.
- 5.Indirect ELISA establishment and preliminary diagnostic testing(confirmatory_validation)
To evaluate whether the same engineered VLP can serve as an effective coating antigen for AKAV serological detection.
Selection: Ability of the VLP-based indirect ELISA to identify AKAV antibody-positive serum with reported sensitivity up to 1:1600 serum dilution.
Steps
- 1.Insert the conserved AKAV Gc neutralizing epitope into the recombinant HBcAg scaffold to produce a chimeric VLPengineered construct
Create a VLP displaying the conserved neutralizing AKAV epitope.
The engineered VLP must be created before it can be verified, used for immunization, or applied as an ELISA antigen.
- 2.Verify successful VLP construction by SDS-PAGE, Western blot, and TEMvalidated construct
Confirm that the engineered VLP expressing the AKAV epitope was successfully constructed.
Verification is performed before biological testing to ensure the intended particle was obtained.
- 3.Immunize mice with the verified VLP and measure antibody responses against AKAV Gcimmunogen
Assess whether the VLP is immunogenic and induces AKAV Gc-specific antibodies.
Immunogenicity testing follows construct verification and precedes functional neutralization testing because antibody generation is required for serum-based antiviral assays.
- 4.Test antisera from VLP-immunized mice for AKAV neutralization and replication inhibition in BHK-21 cells
Determine whether the induced antibodies have functional antiviral activity.
This step follows antibody generation because neutralization testing requires antisera and provides a higher-fidelity functional readout than antigen-binding alone.
- 5.Use the chimeric VLP as coating antigen to establish a preliminary indirect ELISA for AKAV detectiondiagnostic antigen and assay method
Evaluate whether the engineered VLP can function as a coating antigen for serological detection of AKAV antibodies.
After the VLP is shown to be successfully constructed and immunologically relevant, the same antigen is tested for diagnostic utility.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antibody-mediated viral neutralizationantigen presentationvirus-like particle epitope displayTechniques
Functional AssayTarget processes
diagnosticImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: payload burdenoperating role: sensor
The construct requires a recombinant HBcAg scaffold carrying the AKAV Gc epitope and validation by protein/particle assays such as SDS-PAGE, Western blot, and TEM. Its reported evaluation also required mouse immunization, neutralization testing, and ELISA.; requires incorporation of the 1134SVQSFDGKL1142 AKAV Gc epitope into a recombinant HBcAg scaffold; immunogenicity evaluation in the paper used mouse immunization and in vitro neutralization assays; diagnostic use depends on ELISA setup using the VLP as coating antigen
The abstract does not show protective efficacy in target ruminants or establish diagnostic specificity against related viruses. It therefore does not yet solve full vaccine validation or comprehensive field diagnostic benchmarking.; reported as proof-of-concept and preliminary ELISA only; abstract does not report specificity, cross-reactivity, challenge protection, or field-scale validation
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMouseapplication demomouse
Inferred from claim c2 during normalization. The chimeric AKAV epitope-presenting VLP was immunogenic in mice and induced antibodies specific to AKAV Gc protein. Derived from claim c2. Quoted text: Indirect ELISA results indicated that antisera from immunized mice contained antibodies specific to the AKAV Gc protein.
Source:
successMammalian Cell Lineapplication demoBHK-21 cells
neutralization assay
Inferred from claim c3 during normalization. Antisera from mice immunized with the chimeric VLP effectively neutralized AKAV in vitro and inhibited viral replication in BHK-21 cells. Derived from claim c3. Quoted text: neutralization assays demonstrated that the antisera could effectively neutralize AKAV in vitro and inhibit its replication in BHK-21 cells
Source:
Supporting Sources
Ranked Claims
The study successfully constructed a chimeric HBcAg-based VLP presenting the highly conserved neutralizing AKAV Gc epitope 1134SVQSFDGKL1142.
We produced and verified a novel virus-like particle (VLP) by incorporating the neutralizing epitope 1134SVQSFDGKL1142 into a recombinant hepatitis B virus core antigen (HBcAg) scaffold... The successful construction of VLP expressing the AKAV epitope was confirmed by using SDS-PAGE, followed by Western blot (WB) and transmission electron microscopy (TEM).
The VLP-based indirect ELISA successfully identified AKAV antibody-positive serum with detection sensitivity up to a 1:1600 serum dilution.
The developed VLP-based indirect ELISA method successfully identified AKAV antibody-positive serum, with a detection sensitivity of up to a 1:1600 serum dilution.
detection sensitivity 1:1600 serum dilution
The chimeric AKAV epitope-presenting VLP was immunogenic in mice and induced antibodies specific to AKAV Gc protein.
Indirect ELISA results indicated that antisera from immunized mice contained antibodies specific to the AKAV Gc protein.
Antisera from mice immunized with the chimeric VLP effectively neutralized AKAV in vitro and inhibited viral replication in BHK-21 cells.
neutralization assays demonstrated that the antisera could effectively neutralize AKAV in vitro and inhibit its replication in BHK-21 cells
The epitope-presenting VLP provides proof-of-concept as both a promising epitope-based AKAV vaccine candidate and a diagnostic antigen for serological detection.
Collectively, our findings provide proof-of-concept for this epitope-presenting VLP as a promising candidate in the pursuit of a safe and effective epitope-based vaccine against AKAV and also highlight its utility as a diagnostic antigen for serological detection.
Approval Evidence
1 source5 linked approval claimsfirst-pass slug akav-gc-epitope-presenting-hbcag-chimeric-virus-like-particle
We produced and verified a novel virus-like particle (VLP) by incorporating the neutralizing epitope 1134SVQSFDGKL1142 into a recombinant hepatitis B virus core antigen (HBcAg) scaffold.
Source:
constructionsupports
The study successfully constructed a chimeric HBcAg-based VLP presenting the highly conserved neutralizing AKAV Gc epitope 1134SVQSFDGKL1142.
We produced and verified a novel virus-like particle (VLP) by incorporating the neutralizing epitope 1134SVQSFDGKL1142 into a recombinant hepatitis B virus core antigen (HBcAg) scaffold... The successful construction of VLP expressing the AKAV epitope was confirmed by using SDS-PAGE, followed by Western blot (WB) and transmission electron microscopy (TEM).
Source:
diagnostic applicationsupports
The VLP-based indirect ELISA successfully identified AKAV antibody-positive serum with detection sensitivity up to a 1:1600 serum dilution.
The developed VLP-based indirect ELISA method successfully identified AKAV antibody-positive serum, with a detection sensitivity of up to a 1:1600 serum dilution.
Source:
immunogenicitysupports
The chimeric AKAV epitope-presenting VLP was immunogenic in mice and induced antibodies specific to AKAV Gc protein.
Indirect ELISA results indicated that antisera from immunized mice contained antibodies specific to the AKAV Gc protein.
Source:
neutralization activitysupports
Antisera from mice immunized with the chimeric VLP effectively neutralized AKAV in vitro and inhibited viral replication in BHK-21 cells.
neutralization assays demonstrated that the antisera could effectively neutralize AKAV in vitro and inhibit its replication in BHK-21 cells
Source:
utilitysupports
The epitope-presenting VLP provides proof-of-concept as both a promising epitope-based AKAV vaccine candidate and a diagnostic antigen for serological detection.
Collectively, our findings provide proof-of-concept for this epitope-presenting VLP as a promising candidate in the pursuit of a safe and effective epitope-based vaccine against AKAV and also highlight its utility as a diagnostic antigen for serological detection.
Source:
Comparisons
Source-stated alternatives
The source contrasts this VLP approach with broader AKAV vaccination efforts and notes prior work identifying the same neutralizing epitope. The web summary also points to alternative AKAV immunogen and diagnostic formats based on other Gc domains or N-protein ELISA systems.
Source:
The source contrasts this VLP approach with broader AKAV vaccination efforts and notes prior work identifying the same neutralizing epitope. The web summary also points to alternative AKAV immunogen and diagnostic formats based on other Gc domains or N-protein ELISA systems.
Source-backed strengths
reported to be immunogenic in mice; elicited antisera that neutralized AKAV in vitro and inhibited replication in BHK-21 cells; enabled indirect ELISA detection up to 1:1600 serum dilution
Source:
reported to be immunogenic in mice
Source:
elicited antisera that neutralized AKAV in vitro and inhibited replication in BHK-21 cells
Source:
enabled indirect ELISA detection up to 1:1600 serum dilution
Compared with enzyme-linked immunosorbent assay
The source contrasts this VLP approach with broader AKAV vaccination efforts and notes prior work identifying the same neutralizing epitope. The web summary also points to alternative AKAV immunogen and diagnostic formats based on other Gc domains or N-protein ELISA systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: reported to be immunogenic in mice; elicited antisera that neutralized AKAV in vitro and inhibited replication in BHK-21 cells; enabled indirect ELISA detection up to 1:1600 serum dilution.
Relative tradeoffs: reported as proof-of-concept and preliminary ELISA only; abstract does not report specificity, cross-reactivity, challenge protection, or field-scale validation.
Source:
The source contrasts this VLP approach with broader AKAV vaccination efforts and notes prior work identifying the same neutralizing epitope. The web summary also points to alternative AKAV immunogen and diagnostic formats based on other Gc domains or N-protein ELISA systems.
Ranked Citations
- 1.